MorphoSys was founded in Martinsried near Munich in 1992. The founders included Dr. Simon Moroney, today’s CEO of the Company and Prof. Dr. Andreas Plückthun. Today, MorphoSys is one of the world’s leading biotechnology companies in the area of fully human antibodies.








Company founded in Martinsried/Munich, Germany




First commercial partnership with Pharmacia-Upjohn

Move to the Innovation and Start-up Center for Biotechnology (IZB) Martinsried




IPO at the Frankfurt Stock Exchange

Start of an extensive partnership with Bayer AG

Patent dispute begins with Cambridge Antibody Technology




Presentation of the HuCAL antibody library

First HuCAL patent granted




Presentation of the HuCAL GOLD antibody library

Start of a strategic partnership with Schering AG




MorphoSys achieves a settlement of the CAT patent dispute

Dr. Simon E. Moroney receives the Bundesverdienstkreuz am Bande (Cross of the Order of Merit of the Federal Republic of Germany)




Start of a partnership with Pfizer

HuCAL antibodies to combat Alzheimer’s produce positive preclinical results




Start of a strategic partnership with Novartis

Presentation of the new research antibodies division, Antibodies by Design

Inclusion in the technology index TecDAX

MorphoSys achieves break even




The first HuCAL antibodies used in clinics

Acquisition of Biogenesis Group strengthens the research segment

First partnership with a Japanese pharmaceutical group




Acquisition of Serotec Group further strengthens the research segment

HuCAL antibodies to combat Alzheimer’s disease are used in clinics




MorphoSys announces development of new antibody platform technology

MorphoSys and Novartis forge one of the industry’s largest pharma-biotech R&D collaborations




First proprietary therapeutic antibody MOR103 enters clinical trials

MorphoSys unveils new antibody library, HuCAL PLATINUM

First HuCAL antibody enters phase 2 clinical trials




MorphoSys signs first infectious disease alliance with Daiichi-Sankyo



First proprietary therapeutic antibody in a patient setting

First in-licensing of a clinical antibody from Xencor

Aquisition of Sloning BioTechnology

MorphoSys presents new antibody technology arYla



MOR202 enters clinical development

MorphoSys presents new antibody technology Ylanthia

MorphoSys signs first industrial biotechnology alliance with Novozymes


MorphoSys announces positive clinical data for MOR103 in RA and MOR208 in CLL

With gantenerumab from Roche, the first partnered antibody program reaches late stage development

MorphoSys celebrates its 20th anniversary

MorphoSys signs first Ylanthia-based therapeutic partnership


MorphoSys completes sale of AbD Serotec to Bio-Rad

MorphoSys signs license agreement with GlaxoSmithKline for MOR103 program

MorphoSys signs strategic alliance with Celgene for MOR202 program


Product Pipeline

The pipeline is increasingly taking center stage.